This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The intervention was motivational interviewing, in which trained health educators delivered counselling over the telephone about once a month. This was compared with no behavioural intervention. Bisphosphonate therapy consisted of 70mg alendronate weekly.
Location/setting
USA/primary care.
Methods

Analytical approach:
The analysis was based on a state transition model, with individual patient micro-simulations and a lifetime horizon. The authors stated that a societal perspective was adopted.
Effectiveness data:
The clinical data were from a selection of relevant published studies. Assumptions were made for the treatment onset and offset periods. The treatment discontinuation rates and re-initiation without intervention were from an analysis of claims data. The intervention was assumed to reduce treatment discontinuation by 30% among women aged 65 years, based on a review of interventions to improve adherence to osteoporosis medications. The fracture rates were mostly from the Rochester Epidemiology Project Study. The efficacy of bisphosphonate treatment was from a meta-analysis of randomised controlled trials of alendronate in women.
Monetary benefit and utility valuations:
The utility values for various fractures were from published studies.
Measure of benefit:
Quality-adjusted life-years (QALYs) were the summary benefit measure and they were discounted at an annual rate of 3%.
Cost data:
NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination
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The economic analysis included the costs of bisphosphonates, based on their average wholesale price, and the acute and long-term costs of fracture, which were mainly from a study of fracture costs in the USA. The cost of the intervention was assumed by the authors. All costs were in US dollars ($) and a 3% annual discount rate was applied. The price year was 2010.
Analysis of uncertainty:
One-way sensitivity analyses were carried out to investigate uncertainty, using published and assumed ranges of values for selected inputs and focusing on the assumed efficacy and cost of the intervention. Two-way sensitivity analyses were carried out on the intervention cost and effectiveness, for women aged 65, 75, and 85 years. Each analysis was a first-order Monte Carlo simulation.
Results
In a cohort of 65-year-old women, the projected costs without the intervention were $25,149 and the QALYs were 9.273. The hypothetical intervention increased the QALYs to 9.285 at an additional cost of $358, resulting in an incremental cost per QALY gained of $29,571. The incremental cost per QALY gained was $119,161 for 65-year-old men.
The most influential inputs were the cost and efficacy of the intervention and the assumptions for the offset period. When the efficacy of the intervention was reduced to 10%, the cost per QALY rose to $71,566 (for 65-year-old women). When the duration of the intervention effect was reduced from five years to one year the incremental cost per QALY was $136,870.
The results were also sensitive to variations in the cost and effectiveness of bisphosphonates. The cost-effectiveness of the intervention was below the threshold of $50,000 per QALY in most scenarios for 65-year-old women; lower costeffectiveness ratios were found for women aged 75 or 85 years.
